Literature DB >> 17401074

The heart in Anderson-Fabry disease and other lysosomal storage disorders.

Ales Linhart1, Perry M Elliott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17401074      PMCID： PMC1861503          DOI： 10.1136/hrt.2005.063818

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  20 in total

1.  New insights in cardiac structural changes in patients with Fabry's disease.

Authors:  A Linhart; T Palecek; J Bultas; J J Ferguson; J Hrudová; D Karetová; J Zeman; J Ledvinová; H Poupetová; M Elleder; M Aschermann
Journal:  Am Heart J       Date:  2000-06       Impact factor: 4.749

2.  Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.

Authors:  L Klinge; V Straub; U Neudorf; J Schaper; T Bosbach; K Görlinger; M Wallot; S Richards; T Voit
Journal:  Neuromuscul Disord       Date:  2004-11-26       Impact factor: 4.296

3.  Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population.

Authors:  Robert Dobrovolny; Lenka Dvorakova; Jana Ledvinova; Sudheera Magage; Jan Bultas; Jean C Lubanda; Milan Elleder; Debora Karetova; Marketa Pavlikova; Martin Hrebicek
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

Review 4.  Metabolic cardiomyopathies.

Authors:  B Guertl; C Noehammer; G Hoefler
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

5.  Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

Authors:  Jaymin S Shah; Derralynn A Hughes; Bhavesh Sachdev; Maite Tome; Deirdre Ward; Philip Lee; Atul B Mehta; Perry M Elliott
Journal:  Am J Cardiol       Date:  2005-09-15       Impact factor: 2.778

6.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy.

Authors:  Michael Arad; Barry J Maron; Joshua M Gorham; Walter H Johnson; J Philip Saul; Antonio R Perez-Atayde; Paolo Spirito; Gregory B Wright; Ronald J Kanter; Christine E Seidman; J G Seidman
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

7.  Fabry disease: overall effects of agalsidase alfa treatment.

Authors:  M Beck; R Ricci; U Widmer; F Dehout; A García de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; G Houge; U Ramaswami; A Gal; A Mehta
Journal:  Eur J Clin Invest       Date:  2004-12       Impact factor: 4.686

8.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

9.  Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A.

Authors:  P M Elliott; H Kindler; J S Shah; B Sachdev; O E Rimoldi; R Thaman; M T Tome; W J McKenna; P Lee; P G Camici
Journal:  Heart       Date:  2005-08-05       Impact factor: 5.994

10.  Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.

Authors:  Cristina Chimenti; Maurizio Pieroni; Emanuela Morgante; Daniela Antuzzi; Andrea Russo; Matteo Antonio Russo; Attilio Maseri; Andrea Frustaci
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690
View more
  52 in total

Review 1.  Fabry disease, enzyme replacement therapy and the significance of antibody responses.

Authors:  Patrick B Deegan
Journal:  J Inherit Metab Dis       Date:  2011-10-25       Impact factor: 4.982

2.  Electrocardiographic Characterization of Cardiac Hypertrophy in Mice that Overexpress the ErbB2 Receptor Tyrosine Kinase.

Authors:  Polina Sysa-Shah; Lars L Sørensen; M Roselle Abraham; Kathleen L Gabrielson
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

Review 3.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

Authors:  Praveen G Ranganath; Albree Tower-Rader
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

4.  Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS).

Authors:  Tomas Palecek; Jitka Honzikova; Helena Poupetova; Hana Vlaskova; Petr Kuchynka; Lubor Golan; Sudheera Magage; Ales Linhart
Journal:  J Inherit Metab Dis       Date:  2013-10-31       Impact factor: 4.982

5.  Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.

Authors:  A Pisani; L Spinelli; B Visciano; I Capuano; M Sabbatini; E Riccio; G Messalli; M Imbriaco
Journal:  JIMD Rep       Date:  2012-10-21

Review 6.  Rags to riches: Amino acid sensing by the Rag GTPases in health and disease.

Authors:  Owen A Brady; Heba I Diab; Rosa Puertollano
Journal:  Small GTPases       Date:  2016-08-31

Review 7.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

8.  Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy.

Authors:  G Messalli; M Imbriaco; G Avitabile; R Russo; D Iodice; L Spinelli; S Dellegrottaglie; F Cademartiri; M Salvatore; A Pisani
Journal:  Radiol Med       Date:  2011-07-09       Impact factor: 3.469

9.  Auditing the frequency and the clinical and economic impact of testing for Fabry disease in patients under the age of 70 with a stroke admitted to Saint Vincent's University Hospital over a 6-month period.

Authors:  J Lambe; I Noone; R Lonergan; N Tubridy
Journal:  Ir J Med Sci       Date:  2017-05-03       Impact factor: 1.568

10.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.